KeyBanc analyst Brett Fishbin maintains $Alcon (ALC.US)$ with a buy rating, and adjusts the target price from $96 to $107.
According to TipRanks data, the analyst has a success rate of 94.1% and a total average return of 22.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Alcon (ALC.US)$'s main analysts recently are as follows:
The firm maintains a positive outlook on Alcon, expecting a mid-to-high single-digits growth trajectory into the second half of 2024/2025. This optimism is based on continuous market expansion at approximately 5%, along with multiple factors specific to the company. Additionally, the company seems well-prepared to reach its mid-20s EBIT margin goal by the year 2027.
The MedTech sector experienced solid returns, particularly as healthcare providers outperformed within the healthcare sub-sectors. This performance is consistent with the fundamental feedback during Q3, where procedure volumes remained robust and demand was strong. Further research indicates that the sustained demand for procedures is likely to continue into 2025, bolstered by demographic trends and low unemployment rates.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
KeyBanc分析師Brett Fishbin維持$Alcon (ALC.US)$買入評級，並將目標價從96美元上調至107美元。
根據TipRanks數據顯示，該分析師近一年總勝率為94.1%，總平均回報率為22.3%。
此外，綜合報道，$Alcon (ALC.US)$近期主要分析師觀點如下：
該公司對愛爾康保持樂觀的前景，預計到2024/2025年下半年將呈中高個位數的增長軌跡。這種樂觀情緒是基於市場持續擴張約5％，以及公司特有的多種因素。此外，該公司似乎已爲到2027年實現其20年代中期的息稅前利潤率目標做好了充分的準備。
醫療科技行業獲得了可觀的回報，尤其是在醫療保健子行業中醫療保健提供商的表現跑贏大盤的情況下。這一表現與第三季度的基本反饋一致，該季度的手術量保持強勁，需求強勁。進一步的研究表明，在人口趨勢和低失業率的推動下，對手術的持續需求可能會持續到2025年。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
